XBiotech Inc
NASDAQ:XBIT

Watchlist Manager
XBiotech Inc Logo
XBiotech Inc
NASDAQ:XBIT
Watchlist
Price: 2.44 USD 2.52% Market Closed
Market Cap: 74.4m USD

XBiotech Inc
Cash from Operating Activities

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

XBiotech Inc
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
XBiotech Inc
NASDAQ:XBIT
Cash from Operating Activities
-$24m
CAGR 3-Years
-21%
CAGR 5-Years
19%
CAGR 10-Years
1%
Abbvie Inc
NYSE:ABBV
Cash from Operating Activities
$20.9B
CAGR 3-Years
-3%
CAGR 5-Years
5%
CAGR 10-Years
15%
Gilead Sciences Inc
NASDAQ:GILD
Cash from Operating Activities
$9.7B
CAGR 3-Years
0%
CAGR 5-Years
2%
CAGR 10-Years
-6%
Amgen Inc
NASDAQ:AMGN
Cash from Operating Activities
$13.1B
CAGR 3-Years
10%
CAGR 5-Years
4%
CAGR 10-Years
3%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Cash from Operating Activities
$3.7B
CAGR 3-Years
-3%
CAGR 5-Years
3%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Cash from Operating Activities
$5.1B
CAGR 3-Years
-4%
CAGR 5-Years
18%
CAGR 10-Years
15%
No Stocks Found

XBiotech Inc
Glance View

Market Cap
74.4m USD
Industry
Biotechnology

XBiotech, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutic antibodies. The company is headquartered in Austin, Texas and currently employs 97 full-time employees. The company went IPO on 2015-04-15. The firm is focused on the therapies that block a potent substance naturally produced by body, known as interleukin-1 alpha (IL-1a), that mediates tissue breakdown, angiogenesis, the formation of blood clots and inflammation. IL-1a is a protein that is on or in cells of the body and is involved in the body’s response to injury or trauma. Its True Human antibodies have the potential to harness the body's natural immunity to fight disease with increased safety, efficacy and tolerability. The firm has developed a pipeline of product candidates targeting both inflammatory and infectious diseases. The firm is developing a pipeline of product candidates targeting both inflammatory and infectious diseases and has developed commercial scale manufacturing technology and infrastructure.

XBIT Intrinsic Value
Not Available

See Also

What is XBiotech Inc's Cash from Operating Activities?
Cash from Operating Activities
-24m USD

Based on the financial report for Sep 30, 2025, XBiotech Inc's Cash from Operating Activities amounts to -24m USD.

What is XBiotech Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 10Y
1%

Over the last year, the Cash from Operating Activities growth was 13%. The average annual Cash from Operating Activities growth rates for XBiotech Inc have been -21% over the past three years , 19% over the past five years , and 1% over the past ten years .

Back to Top